审视新冠病毒肺炎恢复期血浆治疗中的伦理问题
Reviewing the Ethical Concerns of the Convalescent Plasma Therapy in COVID-19.
作者信息
Raturi Manish, Kala Mansi, Das Kunal, Kusum Anuradha
机构信息
Department of Immunohematology and Blood Transfusion, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehradun, Uttarakhand, India.
Department of Pathology, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehradun, Uttarakhand, India.
出版信息
J Lab Physicians. 2021 Mar;13(1):91-94. doi: 10.1055/s-0041-1727585. Epub 2021 Apr 24.
The understanding of coronavirus disease 2019 (COVID-19) is evolving periodically. There is also a marked increase in COVID-19 patients' demand for the provision of COVID-19 convalescent plasma (CCP) therapy. With the review of the literature, the stage of speculation is quickly moving towards conformity, with the interim guidelines given by the Food and Drug Administration (FDA) in the United States, United Kingdom's blood transfusion services, Saudi's FDA, and the Indian Council for Medical Research, in addition to the European health authorities. It is prudent to address the ethical concerns that merit consideration while harvesting and utilizing CCP as a therapeutic tool in local hospital setting.
对2019冠状病毒病（COVID-19）的认识正在定期更新。COVID-19患者对提供COVID-19康复期血浆（CCP）治疗的需求也显著增加。随着文献综述的进行，推测阶段正迅速走向规范，除了欧洲卫生当局外，美国食品药品监督管理局（FDA）、英国输血服务机构、沙特食品药品监督管理局以及印度医学研究理事会都发布了临时指南。在当地医院环境中采集和使用CCP作为治疗工具时，谨慎处理值得考虑的伦理问题是明智的。
Zotero 插件